GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » Debt-to-Asset

RHHBY (Roche Holding AG) Debt-to-Asset : 0.36 (As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Roche Holding AG Debt-to-Asset?

Roche Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $6,736 Mil. Roche Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $31,797 Mil. Roche Holding AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $107,167 Mil. Roche Holding AG's debt to asset for the quarter that ended in Jun. 2024 was 0.36.


Roche Holding AG Debt-to-Asset Historical Data

The historical data trend for Roche Holding AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Debt-to-Asset Chart

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.18 0.35 0.30 0.34

Roche Holding AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.30 0.30 0.34 0.36

Competitive Comparison of Roche Holding AG's Debt-to-Asset

For the Drug Manufacturers - General subindustry, Roche Holding AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Debt-to-Asset falls into.



Roche Holding AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Roche Holding AG's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5424.376 + 30169.981) / 104611.471
=0.34

Roche Holding AG's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6736.406 + 31796.823) / 107167.151
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG  (OTCPK:RHHBY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Roche Holding AG Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.